Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

por Araujo, John C, Trudel, Geralyn C, Paliwal, Prashni
Publicado 2013

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an e...

por Dayyani, Farshid, Zurita, Amado J., Nogueras-González, Graciela M., Slack, Rebecca, Millikan, Randall E., Araujo, John C., Gallick, Gary E., Logothetis, Christopher J., Corn, Paul G.
Publicado 2016

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer

por Maity, Sankar N., Titus, Mark A., Gyftaki, Revekka, Wu, Guanglin, Lu, Jing-Fang, Ramachandran, S., Li-Ning-Tapia, Elsa M., Logothetis, Christopher J., Araujo, John C., Efstathiou, Eleni
Publicado 2016

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

por Halabi, Susan, Dutta, Sandipan, Tangen, Catherine M, Rosenthal, Mark, Petrylak, Daniel P, Thompson, Ian M, Chi, Kim N, De Bono, Johann S, Araujo, John C, Logothetis, Christopher, Eisenberger, Mario A, Quinn, David I, Fizazi, Karim, Morris, Michael J, Higano, Celestia S, Tannock, Ian F, Small, Eric J, Kelly, William Kevin
Publicado 2020